Become Affiliate

PepFlow

Download

The Calm Fragment

KPV

A tripeptide fragment from the C-terminal end of alpha-MSH, studied for anti-inflammatory signaling in gut, skin, wound, and barrier models.

InflammationGut inflammationSkin inflammationWound repair
TierD
EvidenceLimited
SafetyLimited Data
FDA statusNot Approved
Topical 503AUnder Review
Last reviewed October 25, 2026 24 citations How to read these labels

What is KPV?

KPV is the three-amino-acid sequence Lys-Pro-Val, corresponding to the C-terminal 11-13 fragment of alpha-melanocyte-stimulating hormone. The appeal is that a very small fragment can preserve anti-inflammatory activity without carrying the full parent hormone identity.[7][1]

Most reader interest centers on gut and barrier inflammation. Murine inflammatory-bowel-disease work, nanoparticle oral-delivery research, and hydrogel delivery studies connect KPV with reduced colitis-model inflammation and local tissue targeting.[5][11][15]

KPV names can collapse several related ideas. KPV, Lys-Pro-Val, and alpha-MSH 11-13 point to the tripeptide fragment, while alpha-MSH, melanocortin agonists, and longer peptide analogs are not interchangeable with the same three-amino-acid sequence.[1][7]

What KPV is investigated for

KPV evidence is grouped by practical use case and oral, topical, injectable, rectal, and transdermal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Inflammatory bowel disease and colitis

Oral

44%Preliminary

KPV is promising for gut inflammation biology, but not a substitute for evidence-based IBD care.[5][11]

Human evidence

Controlled human IBD efficacy trials are not established for KPV.[5][11]

Animal / mechanistic evidence

Murine colitis studies support local anti-inflammatory plausibility through KPV and colon-targeted delivery.[5][11]

General inflammatory signaling

Oral, Topical, Injectable

40%Preliminary

General inflammation control should be treated as an anti-inflammatory mechanism, not proof of broad systemic disease benefit.[7]

Human evidence

Broad anti-inflammatory claims lack controlled human outcomes.[7]

Animal / mechanistic evidence

KPV is a minimal fragment with anti-inflammatory activity in vitro and in vivo models.[7]

Gut barrier repair

Oral

32%Limited

Barrier-repair claims are strongest for local oral or colon-targeted delivery models, not systemic injection.[4][17]

Human evidence

No controlled human trial establishes KPV for intestinal barrier repair or permeability outcomes.[4][17]

Animal / mechanistic evidence

PepT1 uptake, nanoparticle delivery, and KPV-binding hydrogel studies support local gut-barrier and mucosal-repair hypotheses in models.[4][11][17]

Skin, wound, and barrier inflammation

Topical, Injectable

30%Limited

Skin and wound claims remain mechanistically plausible but clinically unvalidated.[7][9]

Human evidence

Human route-specific evidence for skin or wound outcomes is limited.[7][9]

Animal / mechanistic evidence

Alpha-MSH/KPV reviews support anti-inflammatory and protective effects in models.[7][9]

Evidence snapshot

15%

Human evidence

Insufficient

No published Phase 2 or Phase 3 human efficacy program establishes KPV for IBD, skin inflammation, or wound healing.[20][22]

48%

Animal / preclinical

Preliminary

Rodent colitis models and targeted oral-delivery work provide the strongest outcome-oriented support. Human route and disease translation remain unresolved.[5][11][15]

44%

Mechanism support

Preliminary

Alpha-MSH fragment biology supports anti-inflammatory signaling. Route-specific translation is still the key limitation.[7][1]

Forms & administration

KPV has oral or sublingual, topical and injectable research presentations. Intracolonic gels and assisted skin-delivery formulations remain experimental, with laboratory or animal evidence. These forms differ in local exposure, absorption and preparation; amounts and application schedules are not interchangeable.[11][9][20][17][12]

OralTopicalInjectableRectalTransdermal

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common oral, sublingual, and injectable protocols use 1-2 mg per dose. Topical amounts depend on the product.[11][9]

Frequency

Usually taken once or twice daily.[5]

Timing Considerations

Morning or evening timing is common.[11]

Cycle Length

Common cycles run 4-8 weeks.[5][11]

What to expect

Weeks 1-2

Gut-focused or skin-focused use may first show quieter stool pattern, less reactive skin, lower itch, or fewer flare spikes when the surrounding routine stays stable.[5][9]

Weeks 4-8

Flare frequency, barrier comfort, and symptom spikes become easier to see as a pattern across a full short cycle.[11][15]

After stopping

Gut or skin calm may hold or drift back toward baseline, especially if diet, wound-care, skin-care, or medication changes continue to shift.[7]

Safety profile

For KPV, oral use raises GI-tolerance and disease-context questions, topical use raises local irritation and formulation questions, and injectable use adds product-quality concerns. Pregnancy, pediatric use, and active IBD or wound-care settings remain higher-caution contexts.[20][22][7]

Common side effects

  • GI discomfort[11]
  • Local irritation[9]

Cautions

  • Active inflammatory disease[5]
  • Unapproved injectable quality[23]

What we don't know

Route-specific absorption, degradation, tissue exposure, formulation behavior, and dose-response are not settled.[9][11]

Who KPV is not for

Route-specific avoid and medical-review notes:

  • Active IBD flare without medical care

    KPV should not delay evidence-based care for diagnosed inflammatory bowel disease or severe symptoms.[5]

  • Pregnancy or breastfeeding

    Avoid because reproductive and developmental safety are not established.[20]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Immunosuppressive therapy

    Immunosuppressive therapy could change infection and inflammatory-disease risk when combined with oral, topical, or injectable KPV; this is a theoretical immune-modulation caution.[7]

Pairing notes

How it works

KPV is the lysine-proline-valine tripeptide from alpha-MSH, and its main rationale is local anti-inflammatory signaling rather than broad immune suppression. Cell and animal work links KPV with reduced inflammatory signaling in epithelial and immune contexts across barrier tissues.[7][2][5]

Delivery is the practical mechanism problem. Oral gut-targeted work depends on small-peptide transport and formulations that keep KPV active at inflamed intestinal sites; topical work depends on skin penetration and stability. Injectable use should not borrow those local-delivery claims without route-specific exposure data.[4][11][10][12]

Research gaps & open questions

What the current literature has not yet settled about KPV:

01

Human trials need to show whether KPV improves inflammatory bowel disease, skin inflammation, or wound healing; current support is mainly laboratory and animal research.[5][11]

02

Oral, topical, and injectable KPV need separate studies showing how much reaches target tissues and how the route changes safety and effect.[9][15]

03

Combinations with other repair peptides need to be studied together before their added benefit and safety can be judged.[7]

Common questions

What is KPV?

KPV is Lys-Pro-Val, a three-amino-acid alpha-MSH fragment studied for local anti-inflammatory signaling in gut, skin, and barrier models.[7]

Is KPV proven for IBD?

No. Oral and gut-targeted KPV rationale comes from animal and formulation studies, not approved human IBD treatment evidence.[5][11]

Is KPV FDA-approved?

No. KPV has no FDA-approved oral, topical, or injectable drug use, and the July 23, 2026 PCAC discussion is not approval.[20][22]

Myths & misconceptions

Myth

Anti-inflammatory means safe for any flare.

Reality

Anti-inflammatory mechanism does not make KPV a substitute for medical care in IBD, infection, or complex skin disease.[5]

Myth

Oral, topical, and injectable KPV are interchangeable.

Reality

Route and formulation matter because gut targeting, skin delivery, and systemic exposure answer different questions.[9][11]

History & discovery

KPV came from alpha-MSH fragment work, where researchers narrowed anti-inflammatory activity to the C-terminal Lys-Pro-Val sequence instead of treating the full melanocortin hormone as the only active unit.[7][1]

Biochemistry and peptide-conformation studies helped define KPV as a compact tripeptide motif tied to alpha-MSH anti-inflammatory signaling.[7][1]

Murine inflammatory bowel disease models connected KPV with intestinal inflammation, PepT1 transport, and barrier-repair hypotheses.[5]

Nanoparticle and hydrogel studies shifted the field toward oral or local delivery systems, while leaving controlled human efficacy unresolved in practice.[11][15]

Published research24 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Bring consistency to your well-being routine.

Use PepFlow to record your KPV protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00